Article
Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib.
Cell biology international - 1 Sept 2018
Wang Jinyao, Wang Yizhe, Zheng Chunlei, Hou Kezuo, Zhang Tieqiong, Qu Xiujuan, Liu Yunpeng, Kang Jian, Hu Xuejun, Che Xiaofang
Abstract excerpt
Tyrosine kinase Inhibitors (TKIs) of epidermal growth factor receptor (EGFR) has considerably benefited for non-small cell lung carcinomas (NSCLC) harbor mutations in EGFR. However, the factors attenuating EGFR-TKI efficiency are obstacles to inhibit the proliferation of EGFR-mutant NSCLC cells successfully. Clarifying the insensitivity mechanisms of EGFR-TKI would help to develop new treatment strategy. In this...
Topics
- Apoptosis
- Carcinoma, Non-Small-Cell Lung
- Cell Line, Tumor
- Cell Proliferation
- Cell Survival
- Crown Ethers
- Drug Resistance, Neoplasm
- ErbB Receptors
- Humans
- Interleukin-6
- Lung Neoplasms
- Mutation
- Protein Kinase Inhibitors